Key Uses and Benefits of Ко-Диован (Co-Diovan)

The combination of valsartan and hydrochlorothiazide is used for managing high blood pressure (hypertension). This fixed-dose combination therapy is generally applied in clinical settings when a patient's blood pressure remains high despite separate treatment with one component.

Therapeutic Domains

This medication is commonly used across conditions presenting with chronic or persistently high blood pressure, and is applicable when symptoms create noticeable functional strain. It plays a role in managing the overall burden of chronic hypertension, which is a condition marked by increased systemic burden.

Patient Benefits

By supporting the reduction of high blood pressure, the combination contributes to easing the overall symptom load. This supportive relief helps patients cope more steadily with conditions marked by increased systemic burden. The approach supports the patient during difficult episodes by easing distress.

---

Quick Fact: Relief for Systemic Imbalance

Co-Diovan assists with maintaining functional stability by addressing groups of symptoms that may appear suddenly or intensify over time, providing supportive relief when symptoms interfere with routine activities.

Eligibility: Who Can and Cannot Use Ко-Диован

Official regulatory documents establish strict criteria regarding the eligibility and contraindications for using Co-Diovan (valsartan/hydrochlorothiazide).

Contraindicated Populations (Must Not Use):

• Pregnancy: Use is strictly prohibited during the second and third trimesters, and the drug must be discontinued immediately upon detection of pregnancy due to the risk of fetal injury and death.
• Hypersensitivity: Patients with known allergy to valsartan, hydrochlorothiazide, other sulfonamide-derived medicines, or any excipients.
• Severe Organ Impairment: Use is prohibited in patients with anuria (no urine production), severe renal impairment (creatinine clearance <30 mL/min), severe hepatic impairment, biliary cirrhosis, or cholestasis.
• Electrolyte/Metabolic Conditions: Prohibited in patients with non-responsive (refractory) hypokalemia, hyponatremia, hypercalcemia, or symptomatic hyperuricemia.
• Drug-Drug Interactions: Contraindicated for concomitant use with aliskiren in patients with diabetes mellitus or moderate-to-severe renal impairment (GFR <60 mL/min/1.73 m^2).

Restricted or Special Consideration:

• Pediatric Use: Use is not recommended for children below the age of 6 years.
• Volume Depletion: The drug is not recommended as initial therapy for patients with pre-existing sodium and/or volume depletion, which must be corrected before treatment begins.
• Lactation: Nursing or the drug should be discontinued, as one component passes into breast milk.

Interactions with other medicines and products

Ко-Диован (valsartan and hydrochlorothiazide) has documented interactions, categorized by mechanism and clinical constraint, based on authoritative government regulatory information.

Interaction Domain	Key Interacting Substances/Classes	Clinical Constraint
Potassium & Electrolyte Modifiers	Potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, corticosteroids, Lithium	Avoid concurrent use with potassium-raising agents; use with Lithium requires careful monitoring of serum levels.
Renin-Angiotensin System Blockers	ACE inhibitors, Angiotensin II Receptor Blockers (ARBs), Aliskiren-containing products	Contraindicated with Aliskiren in patients with diabetes or moderate-to-severe renal impairment (GFR < 60 mL/min/1.73 m^2). Dual blockade is generally not recommended.
Antihypertensive Effect Modifiers	Non-Steroidal Anti-inflammatory Drugs (NSAIDs)	Requires Caution due to risk of reduced blood pressure effect and worsening of renal function. Monitoring of renal function and hydration is advised.
Drug Absorption Alteration	Cholestyramine and Colestipol resins	Requires timing separation of administration to prevent reduced absorption of the hydrochlorothiazide component.

Other agents that may increase serum potassium levels, such as heparin, require caution. Specific inhibitors and inducers of the hepatic transporters OATP1B1/OATP1B3 and MRP2 (e.g., Rifampin, Ritonavir, Ciclosporin) may alter the blood levels of the valsartan component. Alcohol, Barbiturates, and Narcotics may increase the risk of orthostatic hypotension.

Ко-Диован is a fixed-dose combination product containing valsartan and hydrochlorothiazide, each modulating distinct physiological systems.

Valsartan functions as a non-peptide, selective angiotensin II type 1 receptor (AT1) antagonist. It competitively blocks the binding of the endogenous ligand, angiotensin II, to AT1 receptors in tissues such as vascular smooth muscle and the adrenal gland. This receptor blockade inhibits the downstream vasoconstrictive and aldosterone-secreting actions typically mediated by the AT1 receptor, leading to reduced systemic vascular resistance and decreased renal sodium reabsorption.

---

Hydrochlorothiazide, a thiazide diuretic, exerts its effect in the distal convoluted tubule of the nephron. It acts as an inhibitor of the luminal sodium-chloride cotransporter (Na^+/Cl^- cotransporter). This inhibition reduces the reabsorption of Na^+ and Cl^- ions, thereby increasing their delivery to the collecting duct. The resulting increase in tubular fluid osmolarity leads to augmented urinary water excretion, reducing total intravascular fluid volume. System-level consequences include a decrease in plasma volume and, over time, reduced peripheral vascular resistance.

Ко-Диован is administered by the oral route as a fixed-dose film-coated tablet. The medicine is a combination of valsartan and hydrochlorothiazide, available in several strengths for the management of high blood pressure, with strengths ranging up to a combination of 320 mg/25 mg.

The medicine is prescribed for once daily administration as a single dose. A common starting regimen often utilizes the 160 mg valsartan/12.5 mg HCTZ strength. Dosage adjustments, or titrations, are typically assessed and implemented after one to two weeks of current therapy. The maximal blood pressure reduction may take approximately two to four weeks to fully manifest after a change in dose. The total maximum recommended daily intake does not exceed the 320 mg valsartan/25 mg HCTZ strength.

For proper consumption, the tablets may be swallowed with or without food. Administration instructions specify that the film-coated tablet must be swallowed whole and should not be crushed or broken. If a dose is missed, the standard procedure is to skip the missed dose and simply resume the regular schedule the following day; the dose must not be doubled. Furthermore, the combination product is not recommended for use in patients with severe renal impairment (creatinine clearance <30 mL/min).

Research Evidence / Overview of Studies for Ко-Диован

---

Evidence for Use in High Blood Pressure (Hypertension)

This section will summarize the design and reported measurements from clinical trials, including randomized controlled trials (RCTs), that investigated the use of this combination product for use in high blood pressure in adults. Research examined the relationship between this product's use and patterns observed in blood pressure in adults with high blood pressure. Studies were conducted during periods of increased symptom activity, usually short-term, with outcomes monitoring physiological strain or stress as measured by blood pressure readings.

Studies monitored outcomes, and findings describe patterns observed where measurements of blood pressure were recorded over the study period. Research highlights changes measured in both systolic and diastolic blood pressure. The evidence contributes to understanding patterns related to blood pressure readings, specifically how blood pressure figures evolved in the observed populations. Data are still emerging, and certainty remains low regarding the full picture for long-term effects. Research is ongoing to better characterize the extended effects of this product.

---

Summary of Key Study Findings

This part will present the main patterns reported in the research, focusing on what measurements were observed, such as the observed changes in blood pressure readings, and will detail the populations that were included in these studies. Findings indicate that, in the observed populations, the product data showed patterns related to changes in measured blood pressure during the studies. The findings describe group patterns, not personal outcomes, and research provides insight into short-term changes in blood pressure management.

Evidence quality varies across studies, and some subgroup findings are uncertain. While research has explored short-term symptom changes, the long-term effects are not fully established.

---

Evidence in Special Populations

Research examined the product in older adults, and findings describe patterns observed in these specific populations related to blood pressure changes. Data for certain groups remain insufficient. For instance, data are still emerging for its use in patients with certain advanced stages of kidney impairment. Comparative evidence is lacking for other special groups, such as pregnant populations or children, where evidence is limited.

Key Studies & References

1. Evaluation of the Dose Response With Valsartan and Valsartan/Hydrochlorothiazide in Patients With Essential Hypertension (Meta-Analysis)
2. Improving Blood Pressure Control: Increase the Dose of Diuretic or Switch to a Fixed‐Dose Angiotensin Receptor Blocker/Diuretic? The Valsartan Hydrochlorothiazide Diuretic for Initial Control and Titration to Achieve Optimal Therapeutic Effect (Val‐DICTATE) Trial

Common questions about Ко-Диован (FAQ)

---

Q: Can I drink alcohol while taking this medicine?

Official regulatory information states that alcohol should not be consumed while taking this medicine. This is because this medicine and alcohol can intensify each other's effects. The combination may increase side effects such as sleepiness (somnolence) and dizziness.

---

Q: Will this medicine make me sleepy or affect my ability to drive?

Official labeling indicates that this medicine may cause dizziness and somnolence (sleepiness). The warning in official labeling states that these effects could impair the ability to safely drive a car or operate machinery.

---

Q: Is it safe to take this medicine during pregnancy or while breastfeeding?

According to official regulatory sources, there are no adequate studies on pregnant women, but animal studies have shown a potential risk. Regulatory materials note the availability of a pregnancy registry for patients exposed to the medicine during pregnancy. Furthermore, official documentation states that breastfeeding is not recommended due to the potential risk of tumorigenicity (tumor-forming potential) shown in animal studies.

---

Q: Can children use this medicine?

Official product information states that the safety and effectiveness of this medicine have not been established for children younger than 12 years old and adolescents (12 to 17 years old). Therefore, the official regulatory information does not recommend its use in children and adolescents.

---

Q: Can I take this medicine with ibuprofen?

The official regulatory documents detailing drug interactions do not specifically list ibuprofen as a known interaction. However, all other medicines being taken, including over-the-counter products, should be discussed with a healthcare provider or pharmacist, as official labeling encourages a comprehensive discussion about concomitant medications.

Official Storage and Disposal Requirements

Storage and disposal instructions for Co-Diovan (Valsartan/Hydrochlorothiazide) are based strictly on regulatory labeling to ensure product integrity and public safety.

Requirement Area	Regulatory Statement
Temperature & Protection	Do not store above 30 C. Store in the original package to protect from moisture. Keep from freezing.
Container Integrity	Store in the original container. Do not use after the expiry date or if the package is damaged.
Child Safety	Keep this medicine out of the sight and reach of children.
Disposal Instructions	Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to properly throw away medicines you no longer use.

These official statements define how the product must be stored (below 30 C, protected from moisture and freezing) and disposed of (through pharmacy-guided channels), ensuring compliance with environmental protection measures and preventing unauthorized access.